Quantifying binding specificity and drug resistance of protein kinase inhibitors is of funda-mental importance and remains highly challenging due to complex interplay of structural and thermodynamic factors. In this work, molecular simulations and computational alanine scanning are combined with the network-based approaches to characterize molecular de-terminants underlying binding specificities of the ABL kinase inhibitors. The proposed theo-retical framework unveiled a relationship between ligand binding and inhibitor-mediated changes in the residue interaction networks. By using topological parameters, we have described the organization of the residue interaction networks and networks of coevolving residues in the ABL kinase structures. ...
ABSTRACT: Gleevec is a potent inhibitor of Abl tyrosine kinase but not of the highly homologous c-Sr...
<div><p>The AKT signaling pathway has been identified as an important target for cancer therapy. Amo...
Identifying selective kinase inhibitors remains a major challenge. The design of bivalent inhibitors...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Due to its inhibition of the Abl kinase domain in the BCR-ABL fusion protein, imatinib is strikingly...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
SummaryInteractions between kinases and small molecule inhibitors can be activation state dependent....
<p>Binding free energies and alanine scanning of the binding site residues for the ABL-Nilotinib com...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
ABSTRACT: Gleevec is a potent inhibitor of Abl tyrosine kinase but not of the highly homologous c-Sr...
<div><p>The AKT signaling pathway has been identified as an important target for cancer therapy. Amo...
Identifying selective kinase inhibitors remains a major challenge. The design of bivalent inhibitors...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Due to its inhibition of the Abl kinase domain in the BCR-ABL fusion protein, imatinib is strikingly...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
SummaryInteractions between kinases and small molecule inhibitors can be activation state dependent....
<p>Binding free energies and alanine scanning of the binding site residues for the ABL-Nilotinib com...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
The central role of kinases in virtually all signal transduction networks is the driving motivation ...
ABSTRACT: Gleevec is a potent inhibitor of Abl tyrosine kinase but not of the highly homologous c-Sr...
<div><p>The AKT signaling pathway has been identified as an important target for cancer therapy. Amo...
Identifying selective kinase inhibitors remains a major challenge. The design of bivalent inhibitors...